
    study halted early due to no efficacy improvement over aspirin at an interim analysis and very
    little chance of showing overall benefit if study were completed
  
['stroke']
['rivaroxaban (xarelto, bay59-7939)', 'acetylsalicylic acid (aspirin, bay1019036)']

        Inclusion Criteria:

          -  Recent ESUS (between 7 days and 6 months), defined as:

          -  Recent ischemic stroke (including transient ischemic attack with positive
             neuroimaging) visualized by brain imaging that is not lacunar, and

          -  Absence of cervical carotid atherosclerotic stenosis> 50% or occlusion, and

          -  No atrial fibrillation after ≥ 24-hour cardiac rhythm monitoring, and

          -  No intra-cardiac thrombus on either transesophageal or transthoracic echocardiography,
             and

          -  No other specific cause of stroke (for example, arteritis, dissection,
             migraine/vasospasm, drug abuse)

        Exclusion Criteria:

          -  Severely disabling stroke (modified Rankin score ≥4)

          -  Indication for chronic anticoagulation or antiplatelet therapy

          -  Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2
      